Skip to content

Released May 6, 2019, before the open

10-Q filed May 6, 2019, 36 days after period end · 0001144204-19-023895

Q1 2019 · 10-Q
Revenue$10.44M+129.3% vs Q1 2018−61.4% vs Q4 2018
Net Income-$7.26MN/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$0.50N/M vs Q1 2018N/M vs Q4 2018
Operating Income-$5,534,000N/M
Operating Cash Flow-$7,276,000N/M
Free Cash Flowderived-$7,446,000N/M
Margins · derived
Operating margin-53.0%+60.1 pt vs Q1 2018
Net margin-69.6%+89.4 pt vs Q1 2018

What the release said

The release

Same quarter

MetricQ1 2019Q1 2018Q1 2017Q1 2016
Revenue$10.44M$4.55M$2.89M$679.00K
Net Income-$7.26M-$7.24M-$59.15M-$8.60M
EPS Diluted-$0.50-$0.50-$0.48-$0.09

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR